Page 89 - JCTR-11-3

Journal of Clinical and
Translational Research Remdesivir outcomes in hospitalized COVID-19

Table 1. (Continued) Table 4. Complications and clinical outcomes among study
population
Patients’ demographics and baseline n (%) or
characteristics mean±SD (%) Variables n (%) or
C-reactive protein (µg/mL) 106.4±326.2 mean±SD
Ferritin (ng/mL) 641.8±1054.3 Complications
<60 82 (39) Bacterial pneumonia 14 (6.67)
≥60 118 (56.2) Fungal pneumonia 2 (0.95)
Bacteremia 4 (1.9)
Acute respiratory distress syndrome 14 (6.67)
Table 2. Concomitant medications received with remdesivir
Septic shock 9 (4.29)
Concomitant medications n (%) Clinical outcomes
Remdesivir+dexamethasone 101 (48.1) Admitted to ICU 41 (19.52)
Remdesivir+tocilizumab 22 (10.48) Duration of ICU stay (days)* 10.5±11.05
Extracorporeal membrane oxygenation 1 (0.48)
Table 3. Oxygen therapy among the study population Vasopressor support 11 (5.24)

Characteristics of oxygen therapy # n (%) or Length of hospital stay (days)** 14.9±46.29
Mean±SD (%) Death # 26 (12.4)
Administration of oxygen therapy during hospitalization 96 (45.71) Notes: * Indicates duration of ICU stay=Date of ICU discharge – Date
Room air 129 (61) of ICU admission; ** Indicates length of hospital stay=Date of hospital
discharge – Date of hospital admission; # Indicates total number of
Low-flow nasal cannula 86 (40.95) deaths=26; There is one case with no classification pneumonia or not
Duration of low-flow nasal cannula (days)* 4.87±5.42 pneumonia.
Abbreviations: SD: Standard deviation; ICU: Intensive care unit.
High-flow nasal cannula 22 (10.48)
Duration of high-flow nasal cannula (days)* 2.95±4.37
Mechanical ventilation 21 (10)
Duration of mechanical ventilation (days)* 15.15±16.46
Notes: Indicates patient may receive more than one type of oxygen
#
therapy; * Indicates duration of oxygen therapy=End date-Start date.

In addition, patients on mechanical ventilation were
more likely to have longer periods of hospital stays
(mean = 44.461 days) compared to patients with no
mechanical ventilation (mean = 19.179 days) with p<0.001
(Figure 2).
After 30 days of hospital stays, vaccinated patients
showed a higher discharge probability than non-vaccinated Figure 1. Kaplan–Meier curve for length of hospital stay by gender
Notes: *Censored refers to cases who did not have the event till the end of
patients (p=0.043) (Figure 3). the specified or those who lost follow-up; **Censored refers to cases who
did not have the event till the end of the specified time.
4. Discussion
In this study, we described the demographic and clinical
outcomes of hospitalized COVID-19 patients who (80.1%), followed by cough (62.6%) and shortness of breath
received RDV at a hospital center in KSA. About 52.4% (41.1%). Here, 180 patients have received COVID-19
of our population has pneumonia. The mean ± SD age vaccine. Among them, 40.6% and 50% of patients received
was 57.43 ± 18.4 years, and 56.1% were female. In our two and three doses, respectively.
cohort, hypertension (54.76%), diabetes (44.76%), and Moreover, dexamethasone (48.1%) and tocilizumab
cardiovascular disease (30%) were the most common (10.48%) were frequently administered with RDV as
comorbidities among COVID-19 patients receiving RDV. combination therapeutic regimens. Oxygen therapy
As for the clinical symptoms, the most initial common was required in 45.7% of the patients, with 40.95% and
symptom of COVID-19 among our cohort was fever 10.48% of patients needed low-flow and high-flow nasal

Volume 11 Issue 3 (2025) 83 doi: 10.36922/jctr.24.00027